Terms: = Ovarian cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
167 results:
1. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
2. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
3. Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
Jamalzadeh S; Dai J; Lavikka K; Li Y; Jiang J; Huhtinen K; Virtanen A; Oikkonen J; Hietanen S; Hynninen J; Vähärautio A; Häkkinen A; Hautaniemi S
BMC Cancer; 2024 Feb; 24(1):173. PubMed ID: 38317080
[TBL] [Abstract] [Full Text] [Related]
4. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
5. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in kras-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract] [Full Text] [Related]
6. ovarian Mesonephric-like Adenocarcinoma Recurring With a Rhabdomyosarcoma Component: A Case Report.
Yamamoto A; Nagai T; Sukeda A; Kajiwara M; Fukunaga M; Sasaki T; Kinoshita Y; Hayashi M; Hayashi S; Ono M; Futagami M; Nishi H
Int J Gynecol Pathol; 2024 May; 43(3):296-301. PubMed ID: 38085954
[TBL] [Abstract] [Full Text] [Related]
7. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
8. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
[TBL] [Abstract] [Full Text] [Related]
9. treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
10. Mesonephric-like adenocarcinoma of the female genital tract: possible role of kras-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic kras-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract] [Full Text] [Related]
11. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal cancer Cells: Implications in Therapy.
Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
[TBL] [Abstract] [Full Text] [Related]
12. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract] [Full Text] [Related]
13. A prediction model to refine the timing of an early second-look laparoscopic exploration in patients with colon cancer at high risk of early peritoneal metastasis recurrence.
Fawaz J; Pocard M; Liberale G; Eveno C; Malgras B; Sideris L; Hübner M; Sabbagh C; Sgarbura O; Taibi A; Hobeika C
J Surg Oncol; 2023 Sep; 128(4):576-584. PubMed ID: 37226983
[TBL] [Abstract] [Full Text] [Related]
14. Histological and Genetic Diversity in ovarian Mucinous Carcinomas: A Pilot Study.
Razia S; Nakayama K; Yamashita H; Ishibashi T; Ishikawa M; Kanno K; Sato S; Kyo S
Curr Oncol; 2023 Apr; 30(4):4052-4059. PubMed ID: 37185420
[TBL] [Abstract] [Full Text] [Related]
15. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
[TBL] [Abstract] [Full Text] [Related]
16. Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S; Wolfer A; Bisig B; Missiglia E; Tiab A; Kamel EM; Michielin O; Coukos G; Homicsko K
Cancer Biol Ther; 2023 Dec; 24(1):2193116. PubMed ID: 36967525
[TBL] [Abstract] [Full Text] [Related]
17. PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia.
Xue Y; Dong Y; Lou Y; Lv Q; Shan W; Wang C; Chen X
J Gynecol Oncol; 2023 Jul; 34(4):e53. PubMed ID: 36929579
[TBL] [Abstract] [Full Text] [Related]
18. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells.
Kollara A; Burt BD; Ringuette MJ; Brown TJ
Cell Signal; 2023 Jun; 106():110634. PubMed ID: 36828346
[TBL] [Abstract] [Full Text] [Related]
19. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract] [Full Text] [Related]
20. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
[Next]
